Related Experiment Videos
CPAP treatment of obstructive sleep apnoea and neurodevelopmental deficits
1Jacobo Lichtmann Apnoea Investigation Unit, Department of Paediatrics, Bnai Zion Medical Centre, Haifa, Israel.
Insights
Continuous Positive Airway Pressure (CPAP) effectively treated obstructive sleep apnea in boys with neurodevelopmental deficits. This therapy improved sleep, reduced seizures, and enhanced overall health, proving beneficial even in complex cases.
Area of Science:
- Pediatric Neurology
- Sleep Medicine
- Neurodevelopmental Disorders
Background:
- Obstructive sleep apnea (OSA) is prevalent in children with neurodevelopmental deficits.
- Previous treatments for OSA in this population have shown limited success.
Purpose of the Study:
- To evaluate the efficacy of Continuous Positive Airway Pressure (CPAP) in treating obstructive sleep apnea (OSA) in children with neurodevelopmental deficits.
- To assess clinical and polysomnographic outcomes following CPAP therapy.
Main Methods:
- Case series of four boys (ages 6-16) with neurodevelopmental deficits and diagnosed OSA.
- Treatment involved CPAP therapy over a follow-up period of 12-48 months.
- Clinical assessments and polysomnography were used to evaluate treatment effectiveness.
Main Results:
- CPAP treatment led to significant improvements in sleep quality, daily arousal, and reduced seizure frequency and pneumonia episodes.
- Polysomnography revealed marked improvements in apnea frequency, awakenings, sleep efficiency, and arterial oxygen saturation.
- Reported side effects were mild and manageable.
Conclusions:
- CPAP is a viable and effective treatment for intractable obstructive sleep apnea in children, including those with co-occurring neurodevelopmental deficits.
- The therapy offers substantial clinical and polysomnographic benefits, improving quality of life and health outcomes.
Abstract:
Four boys aged 6-16 years with neurodevelopmental deficits were treated with CPAP for obstructive sleep apnoea. Their diagnoses were: Obesity with mild mental retardation, (2) attention deficit hyperactivity disorder, (3) epilepsy associated with left hemiparesis and (4) mild mental retardation due to fragile X syndrome. Previous therapeutic attempts, including adenotonsillectomy, amitriptyline and methylphenidate in our patients prior to CPAP treatment were unsuccessful. A follow-up period of 12-48 months demonstrated a number of clinical benefits such as improvement in sleep quality and daily arousal, and a decrease in the frequency of seizures and episodes of pneumonia. Polysomnographic studies indicated a significant improvement in sleep parameters such as apnoea frequency, awakenings, sleep efficiency and arterial oxygen saturation. Side effects were mild and readily alleviated. CPAP is a feasible therapeutic intervention in intractable obstructive sleep apnoea of childhood, even when associated with neurodevelopmental deficits.